Trial Profile

Phase 3 trial of Revascor in patients with advanced heart failure patients at high risk of recurrent heart failure-related hospitalization and death

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 29 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Nov 2019 According to a Mesoblast media release, Full accrual of primary endpoints expected around the end of this year and data read-out is planned in H1 CY20.
25 Feb 2019 New trial record
19 Feb 2019 Tasly Pharmaceutical Group is planning to meet with the National Medical Products Administration (NMPA) of China( the China Food and Drug Administration), in the first quarter 2019 to discuss the regulatory approval with the objective is to initiate this trial. Tasly and Mesoblast will leverage each other's clinical trial results in China, the United States and other territories to support their respective regulatory submissions.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com